Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (åpner nytt vindu)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Kilde‎: Cancer 2013;119(21):3784-7.

Arkiv‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (åpner nytt vindu)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (åpner nytt vindu)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Kilde‎: Lancet 1989;334(8655):122-4.

Arkiv‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (åpner nytt vindu)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (åpner nytt vindu)

Ben-Bassat I, Douer D, Ramot B.

Kilde‎: Eur J Haematol 1990;45(2):86-9.

Arkiv‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (åpner nytt vindu)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (åpner nytt vindu)

Dean A, Tuffin P.

Kilde‎: J Pain Symptom Manage 1997;13(1):20-4.

Arkiv‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (åpner nytt vindu)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (åpner nytt vindu)

Ford PA, Grant SJ, Mick R, Keck G.

Kilde‎: J Clin Oncol 2015;33(15):1674-9.

Arkiv‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (åpner nytt vindu)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (åpner nytt vindu)

Garewal HS, Durie BG.

Kilde‎: Scand J Haematol 1985;35(5):497-500.

Arkiv‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (åpner nytt vindu)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (åpner nytt vindu)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Kilde‎: Cancer 2006;107(1):136-40.

Arkiv‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (åpner nytt vindu)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (åpner nytt vindu)

Marshall A, Li A, Drucker A, Dzik W.

Kilde‎: Hematol Oncol 2016;34(3):147-53.

Arkiv‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (åpner nytt vindu)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (åpner nytt vindu)

Prokopchuk-Gauk O, Brose K.

Kilde‎: Cureus 2015;7(12):e428.

Arkiv‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (åpner nytt vindu)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (åpner nytt vindu)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Kilde‎: Leuk Lymphoma 1995;19(1-2):141-4.

Arkiv‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (åpner nytt vindu)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (åpner nytt vindu)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Kilde‎: Hematol Oncol 2008;26(4):241-6.

Arkiv‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (åpner nytt vindu)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (åpner nytt vindu)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Kilde‎: Am J Hematol 2006;81(9):720.

Arkiv‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (åpner nytt vindu)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (åpner nytt vindu)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Kilde‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

Arkiv‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (åpner nytt vindu)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (åpner nytt vindu)

Erduran E, Bahadir A, Mutlu M.

Kilde‎: Eur J Clin Med Oncol 2011;3(5):1-4.

Arkiv‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (åpner nytt vindu)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (åpner nytt vindu)

Franchini M, Veneri D, Lippi G.

Kilde‎: Bone Marrow Transplant 2007;39(12):729-35.

Arkiv‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (åpner nytt vindu)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (åpner nytt vindu)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Kilde‎: Am J Hematol 2002;69(3):219-22.

Arkiv‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (åpner nytt vindu)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (åpner nytt vindu)

Hsieh A, Cheong I.

Kilde‎: Am J Emerg Med 2007;25(9):1085.e1-2.

Arkiv‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (åpner nytt vindu)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (åpner nytt vindu)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Kilde‎: Haemostasis 1996;26 Suppl 1:159-64.

Arkiv‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (åpner nytt vindu)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (åpner nytt vindu)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Kilde‎: Med Oncol 2010;27(1):16-9.

Arkiv‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (åpner nytt vindu)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (åpner nytt vindu)

Vidarsson B, Önundarson PT.

Kilde‎: Thromb Haemost 2000;83(4):634-5.

Arkiv‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (åpner nytt vindu)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (åpner nytt vindu)

Zver S, Andoljšek D, Černelč P.

Kilde‎: Eur J Haematol 2004;72(6):455-6.

Arkiv‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (åpner nytt vindu)

Management of bleeding complications of hematologic malignancies. (åpner nytt vindu)

Green D.

Kilde‎: Semin Thromb Hemost 2007;33(4):427-34.

Arkiv‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (åpner nytt vindu)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (åpner nytt vindu)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Kilde‎: Int J Lab Hematol 2013;35(4):457-9.

Arkiv‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (åpner nytt vindu)

Management of bleeding in patients with advanced cancer. (åpner nytt vindu)

Pereira J, Phan T.

Kilde‎: Oncologist 2004;9(5):561-70.

Arkiv‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (åpner nytt vindu)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (åpner nytt vindu)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Kilde‎: Haematologica 1997;82(5):584-7.

Arkiv‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (åpner nytt vindu)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (åpner nytt vindu)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Kilde‎: Bull Cancer 2006;93(2):E7-12.

Arkiv‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (åpner nytt vindu)